OBiO Tech(688238)

Search documents
和元生物:关于召开2023年第三季度业绩说明会的公告
2023-10-25 13:01
证券代码:688238 证券简称:和元生物 公告编号:2023-046 和元生物技术(上海)股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: (一) 会议召开时间:2023 年 11 月 9 日下午 13:00-14:00 ( 二 ) 会 议 召 开 地 点 : 上 海 证 券 交 易 所 上 证 路 演 中 心 ( 网 址 : http://roadshow.sseinfo.com/) 投资者可于 2023 年 11 月 2 日(星期四) 至 11 月 8 日(星期三)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zhengquanbu@obiosh.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 和元生物技术(上海)股份有限公司(以下简称"公司")已于 2023 年 10 月 26 日披露公司《2023 年第三季度报告》,为便于广大投资者 ...
和元生物:关于首次公开发行部分限售股上市流通公告
2023-10-19 08:51
证券代码:688238 证券简称:和元生物 公告编号:2023-045 本次上市流通的限售股数量为 507,000 股。 本次上市流通的日期为 2023 年 10 月 30 日(因 2023 年 10 月 28 日为非交易 日,上市流通日顺延)。 和元生物技术(上海)股份有限公司 关于首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 11 日出具的《关于同意和元 生物技术(上海)股份有限公司首次公开发行股票注册的批复》(证监许可 〔2022〕61 号),同意和元生物技术(上海)股份有限公司(以下简称"公司" 或"和元生物")首次公开发行股票的注册申请。经上海证券交易所同意,公司 首次向社会公众公开发行人民币普通股(A股)股票100,000,000股,并于2022 年 3 月 22 日在上海证券交易所科创板上市,发行完成后总股本为 493,189,000 股,其中有限售条件流通股 424,181 ...
和元生物:海通证券股份有限公司关于和元生物技术(上海)股份有限公司首次公开发行部分限售股上市流通的核查意见
2023-10-19 08:51
公司于 2023 年 5 月 16 日召开 2022 年年度股东大会,审议通过了《关于 <2022 年年度利润分配及资本公积转增股本方案>的议案》,以资本公积金向全体 股东每 10 股转增 3 股。以截至 2022 年 12 月 31 日,公司总股本 493,189,000 股, 合计拟转增 147,956,700 股,转增后公司总股本变更为 641,145,700 股。公司以 2023 年 5 月 29 日为股权登记日实施权益分派,实施完成后,公司总股本已变更 为 641,145,700 股。 海通证券股份有限公司关于 和元生物技术(上海)股份有限公司 首次公开发行部分限售股上市流通的核查意见 海通证券股份有限公司(以下简称海通证券或保荐机构)作为和元生物技术 (上海)股份有限公司(以下简称和元生物或公司)首次公开发行股票并上市持 续督导保荐机构,根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》《上海证券交易所上市公司自律监管指引第11号——持续督 导》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等有关 规定,对和元生物首次公开发行部分限售股上市流通事项进行了核查 ...
和元生物:关于首次公开发行部分限售股上市流通公告
2023-09-14 09:12
证券代码:688238 证券简称:和元生物 公告编号:2023-044 和元生物技术(上海)股份有限公司 关于首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 11 日出具的《关于同意和元 生物技术(上海)股份有限公司首次公开发行股票注册的批复》(证监许可 〔2022〕61 号),同意和元生物技术(上海)股份有限公司(以下简称"公司" 或"和元生物")首次公开发行股票的注册申请。经上海证券交易所同意,公司 首次向社会公众公开发行人民币普通股(A股)股票100,000,000股,并于2022 年 3 月 22 日在上海证券交易所科创板上市,发行完成后总股本为 493,189,000 股,其中有限售条件流通股 424,181,006 股,占公司发行后总股本的 86.01%,无 限售条件流通股为 69,007,994 股,占公司发行后总股本的 13.99%。 本次上市流通的限售股为公司首次公开发行部 ...
和元生物:海通证券股份有限公司关于和元生物技术(上海)股份有限公司首次公开发行部分限售股上市流通的核查意见
2023-09-14 09:10
海通证券股份有限公司关于 和元生物技术(上海)股份有限公司 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于2022年1月11日出具的《关于同意和元生物 技术(上海)股份有限公司首次公开发行股票注册的批复》(证监许可〔2022〕 61号),同意公司首次公开发行股票的注册申请。经上海证券交易所同意,公司 首次向社会公众公开发行人民币普通股(A股)股票100,000,000股,并于2022年 3月22日在上海证券交易所科创板上市,发行完成后总股本为493,189,000股,其 中有限售条件流通股424,181,006股,占公司发行后总股本的86.01%,无限售条件 流通股为69,007,994股,占公司发行后总股本的13.99%。 本次上市流通的限售股为公司首次公开发行部分限售股,限售股股东数量为 9名,限售期为自限售股股东取得公司股份之日起36个月,该部分限售股股东对 应的限售股合计为76,357,580股,占公司目前股本总数的11.7939%。其中,包含 因公司实施2022年年度权益分派,以资本公积金向全体股东每10股转增3股,获 得的转增股份17,620,980股。现锁定期即将届满,该部分限售股将 ...
和元生物:海通证券股份有限公司关于和元生物技术(上海)股份有限公司2023年半年度持续督导跟踪报告
2023-09-01 09:36
海通证券股份有限公司 关于和元生物技术(上海)股份有限公司 经中国证券监督管理委员会《关于同意和元生物技术(上海)股份有限公司 首次公开发行股票注册的批复》(证监许可[2022]61 号)核准,和元生物技术(上 海)股份有限公司(以下简称"上市公司"、"和元生物"、"公司")首次公 开发行股票 10,000.00 万股,每股面值人民币 1.00 元,每股发行价格人民币 13.23 元,募集资金总额为人民币 1,323,000,000.00 元,扣除发行费用后,实际募集资 金净额为人民币 1,197,464,432.14 元。截至 2022 年 3 月 17 日,上述募集资金已 全部到位,天健会计师事务所(特殊普通合伙)对公司本次公开发行新股的募集 1 资金到位情况进行了审验并出具了天健验【2022】6-10 号《验资报告》。本次发 行证券已于 2022 年 3 月 22 日在上海证券交易所上市。海通证券股份有限公司(以 下简称"保荐机构"或"海通证券")担任其持续督导保荐机构,持续督导期间 为 2022 年 3 月 22 日至 2025 年 12 月 31 日。 在 2023 年 1 月 1 日至 2023 ...
和元生物(688238) - 2023 Q2 - 季度财报
2023-08-23 16:00
Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[2]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 25% year-over-year growth[22]. - The company achieved operating revenue of CNY 83.75 million, a decrease of 37.92% compared to the same period last year[25]. - The net profit attributable to shareholders was CNY -44.80 million, representing a decline of 323.70% year-over-year[25]. - The basic earnings per share were CNY -0.070, down 255.56% from CNY 0.045 in the previous year[24]. - The gross margin improved to 60%, up from 55% in the previous year, due to operational efficiencies[22]. - The net cash flow from operating activities was CNY -63.14 million, indicating a significant decline in cash generation capabilities[25]. - The total assets at the end of the reporting period were CNY 2.51 billion, a slight increase of 0.83% from the previous year[25]. - The net assets attributable to shareholders decreased to CNY 2.13 billion, down 1.85% from the end of the previous year[25]. User Growth and Market Expansion - User data indicates a growing customer base, with active users increasing by 15% to 1.2 million by the end of June 2023[2]. - User data indicates a growth in active users, with a 15% increase compared to the previous year, reaching 500,000 active users[22]. - The company is expanding its market presence, targeting an increase in international sales by 20% in the next six months[2]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by the end of 2024[22]. Research and Development - Ongoing research and development efforts have led to the filing of three new patents related to gene editing technologies[2]. - The company has invested 200 million RMB in R&D for innovative therapies, focusing on rare diseases and personalized medicine[22]. - The company is focusing on enhancing its R&D capabilities in mRNA and exosome technologies, which are critical for future growth[26]. - The company has developed a strong R&D capability, focusing on new or improved gene therapy vectors based on market demand and industry trends[39]. - The company has achieved significant advancements in lentiviral vector research, including the development of novel lentiviral vectors that enhance infection capabilities in immune cells, surpassing mainstream alternatives[76]. - The company has optimized the oncolytic virus vector production system, significantly improving yield and quality, thereby enhancing its technical service capabilities in the adenovirus sector[96]. - R&D expenses surged by 71.71% year-on-year to ¥24,338,797.45, reflecting the company's increased investment in R&D and expansion of its R&D team[127]. Strategic Partnerships and Acquisitions - The company has initiated discussions for potential mergers and acquisitions to enhance its product portfolio and market reach[2]. - A new strategic partnership has been established with a leading biotech firm to co-develop innovative therapies, expected to yield results by Q4 2023[2]. - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in gene therapy[22]. Market Trends and Industry Insights - The gene therapy market is experiencing rapid growth, supported by national and local policies promoting biopharmaceutical innovation, with increasing investment and financing in the industry[34]. - The global market for gene and cell therapy products is projected to reach 7.4 billion USD in 2023, with a compound annual growth rate of over 43.5% from 2021 to 2028, potentially reaching nearly 50 billion USD by 2028[52]. - The investment landscape in gene and cell therapy is rapidly evolving, with 56 cell therapy products making clinical progress in the first half of 2023, indicating a robust pipeline of innovative treatments[51]. Regulatory Environment - Regulatory bodies in both China and the U.S. are issuing guidelines to ensure the healthy development of gene and cell therapy products, enhancing compliance and quality assurance[65]. - The implementation of the "Human Genetic Resources Management Regulations" effective from July 1, 2023, is expected to standardize the regulation of human genetic resources, promoting the healthy development of the gene and cell therapy industry[67]. Environmental Commitment - The company has established an environmental management system and has not faced any significant environmental accidents or legal penalties during the reporting period[160]. - The company is committed to reducing its carbon emissions and has implemented measures to lower energy consumption[161]. Shareholder Commitments and Governance - The company has a commitment to avoid related party transactions and prevent fund occupation, effective from May 29, 2021, on a long-term basis[167]. - The company has a profit distribution policy commitment, ensuring returns to shareholders[169]. - The company will ensure timely and accurate disclosure of information regarding stock reduction plans to maintain transparency with investors[192].
和元生物:关于召开2023年半年度业绩说明会的公告
2023-08-23 11:18
证券代码:688238 证券简称:和元生物 公告编号:2023-043 和元生物技术(上海)股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 投资者可于 2023 年 8 月 24 日(星期四) 至 8 月 30 日(星期三)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zhengquanbu@obiosh.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 和元生物技术(上海)股份有限公司(以下简称"公司")已于 2023 年 8 月 24 日披露公司《2023 年半年度报告》,为便于广大投资者更全面深入地了解公 司 2023 年半年度经营成果、财务状况,公司计划于 2023 年 8 月 31 日下午 13:00- 14:00 举行 2023 年半年度业绩说明会,就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开,公 ...
和元生物(688238) - 2023 Q1 - 季度财报
2023-04-26 16:00
Financial Performance - The company's revenue for Q1 2023 was CNY 30,791,377, representing a decrease of 57.89% compared to the same period last year[5]. - The net profit attributable to shareholders was -CNY 31,743,281.26, a decline of 363.00% year-over-year[5]. - The basic earnings per share (EPS) was -CNY 0.0644, down 309.77% from the previous year[6]. - The net profit for Q1 2023 was -31,806,061.95 RMB, compared to a net profit of 12,069,474.76 RMB in Q1 2022, indicating a significant decline[25]. - Operating profit for Q1 2023 was a loss of ¥32,492,918.48, compared to a profit of ¥13,478,822.68 in Q1 2022[24]. - The total comprehensive income for Q1 2023 was -31,926,525.95 RMB, compared to 12,069,474.76 RMB in Q1 2022, showing a substantial decrease[25]. Research and Development - R&D expenses totaled CNY 11,269,831.53, an increase of 58.80% compared to the same period last year, accounting for 36.60% of revenue, up 26.89 percentage points[6]. - The company is focused on providing leading-edge, ready-to-use, and cost-effective biological reagent products to enhance R&D efficiency in the life sciences sector[16]. - Research and development expenses increased to CNY 10,186,117.74 in Q1 2023, up 57.5% from CNY 6,476,625.35 in Q1 2022[34]. Cash Flow and Liquidity - The net cash flow from operating activities was -CNY 32,994,071.49, indicating a significant cash outflow[5]. - Operating cash flow for Q1 2023 was -32,994,071.49 RMB, compared to -29,414,344.01 RMB in Q1 2022, reflecting a worsening cash flow situation[27]. - The company’s cash flow from operating activities was significantly negative, indicating challenges in maintaining operational liquidity[27]. - The company reported cash inflows from investment activities of 135,357,049.87 RMB in Q1 2023, with cash outflows of 427,377,366.68 RMB, resulting in a net cash flow from investment activities of -292,020,316.81 RMB[28]. - The company’s cash flow from financing activities in Q1 2023 was 134,792,214.05 RMB, a significant decrease from 1,284,012,398.16 RMB in Q1 2022[28]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,505,295,721.15, a slight increase of 0.61% from the end of the previous year[6]. - Total liabilities as of March 31, 2023, were ¥362,527,460.23, up from ¥318,879,989.48 at the end of 2022, an increase of 13.66%[22]. - The total current liabilities were CNY 186,933,628.19, with a breakdown including accounts payable of CNY 36,536,205.82 and contract liabilities of CNY 19,573,347.75[41]. - The total non-current liabilities amounted to CNY 131,946,361.29, a decrease from CNY 138,339,121.54[41]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,988[12]. - The largest shareholder, Pan Oudong, holds 94,465,800 shares, representing 19.15% of total shares[12]. Investments and Projects - The company has completed the overseas investment project registration for its subsidiary OBiO TECH, INC, with an initial investment of $2.4 million[16]. - The "He Yuan Intelligent Manufacturing Precision Medical Industry Base" opened in Shanghai with a total investment of approximately RMB 1.5 billion, covering an area of 77,000 square meters[18]. - As of March 31, 2023, over RMB 700 million has been invested in the first phase of the medical industry base project, which is expected to officially commence production in the second half of the year[18]. - The company established a joint venture with Shanghai Li Ji Biotechnology Co., Ltd. and Shanghai Li Ji Pharmaceutical Technology Co., Ltd., holding a 60% stake[16]. - The company participated as a limited partner in the establishment of the Shanghai Hongsheng Houde Private Equity Fund, which has completed registration and obtained the private fund filing certificate[17]. Workforce - The company has increased its workforce to 648 employees as of the end of the first quarter of 2023[16].
和元生物(688238) - 2022 Q4 - 年度财报
2023-04-19 16:00
Financial Performance - The company reported a net profit attributable to shareholders of RMB 39.0252 million for the year 2022[6]. - The net profit attributable to shareholders of the listed company was CNY 39.03 million, a decrease of 28.07% compared to the previous year[27]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 30.80 million, a year-on-year decrease of 24.87%[42]. - The company achieved operating revenue of CNY 291.30 million in 2022, representing a year-on-year increase of 14.26%[27]. - The company achieved total revenue of 291.30 million RMB, representing a year-on-year growth of 14.26%[162]. - The gross profit margin for the biopharmaceutical sector decreased by 6.64 percentage points to 44.72%[170]. - The gross profit margin of CDMO services is subject to fluctuations, particularly in early-stage projects, which typically have lower margins[156]. - Operating cash flow decreased by 80.40% to 21.42 million RMB, primarily due to delayed customer payments[165]. - The overall operating costs rose by 30.52% to 161.93 million RMB, aligning with the increase in revenue[165]. Share Capital and Dividends - The company plans to increase its total share capital from 493,189,000 shares to 641,145,700 shares by issuing 147,956,700 new shares to shareholders[6]. - The company will not distribute cash dividends or bonus shares for the year 2022, opting instead for a capital reserve conversion[6]. - The board of directors has approved the profit distribution plan, pending approval from the shareholders' meeting[7]. Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[4]. - The report includes forward-looking statements that are subject to various uncertainties and risks[9]. - The company faces risks related to client drug commercialization, which could impact CDMO service demand and profitability if projects do not progress as expected[152]. - The company is at risk of talent shortages in a rapidly growing industry, which could adversely affect R&D efforts and project execution[153]. - Increased competition in the gene therapy CDMO sector may challenge the company's market position if it fails to continuously upgrade its technology and services[155]. Research and Development - The company plans to invest 200 million RMB in research and development over the next two years to accelerate innovation[19]. - The company increased its R&D investment as a percentage of operating revenue to 11.96%, up by 2.7 percentage points from the previous year[29]. - R&D expenditure for the year was RMB 34.83 million, an increase of 47.47% year-on-year[47]. - The total R&D expenditure for the year reached approximately 34.83 million yuan, a 47.47% increase from the previous year, representing 11.96% of total revenue, up from 9.26%[127][128]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 30% based on new product launches and market expansion strategies[19]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[19]. - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in cell and gene therapy[19]. - The company is actively expanding its influence in the U.S. market through industry exhibitions, client visits, and academic presentations[101]. Product Development and Innovation - New product development includes advancements in gene editing technologies, with expected market introduction in Q3 2023[19]. - The company has established a new cell bank facility to support its product development and ensure quality control[19]. - The company has developed a new "BigAdeno" large-capacity adenoviral vector packaging system, capable of exceeding 10Kb gene carrying capacity, and has initiated several R&D production collaborations[117]. - The company is focusing on enhancing the efficacy of gene therapy vectors through various optimizations, resulting in significant improvements at both cellular and animal levels[119]. Financial Position and Assets - Total assets at the end of 2022 reached CNY 2,490.08 million, an increase of 97.09% from the beginning of the year[30]. - The net assets attributable to shareholders of the listed company grew by 136.60% to CNY 2,171.97 million by the end of 2022[30]. - Cash and cash equivalents at the end of the period were 1,243,842,147.66 RMB, accounting for 49.95% of total assets, primarily due to funds raised from stock issuance[190]. - Accounts receivable increased by 169.87% to 77,808,946.94 RMB, mainly due to delayed payments from CDMO business clients[190]. Client and Supplier Relationships - The top five customers contributed ¥97.68 million in sales, representing 33.54% of the annual total sales[177]. - The top five suppliers accounted for 2,150.58 million RMB in purchases, which is 24.07% of the total annual purchases[181]. - The company has established a broad customer base, including renowned gene therapy companies and top research institutions, enhancing its market competitiveness[144]. Industry Trends and Market Outlook - The global gene therapy market size grew from $50.4 million in 2016 to $2.08 billion in 2020, with a projected size of nearly $30.54 billion by 2025, representing a CAGR of 70% from 2020 to 2025[72]. - The Chinese CGT market is expected to reach $2.59 billion by 2025, with a CAGR of 276% from 2020 to 2025[72]. - The gene therapy industry is experiencing short-term challenges but is expected to have long-term growth potential due to the approval of multiple gene therapy drugs in 2022 and improvements in insurance coverage for these treatments[76].